View Future GrowthCannaPharmaRX 過去の業績過去 基準チェック /06CannaPharmaRXは27.8%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで9.7%毎年増加している。売上は成長しており、年平均87.9%の割合である。主要情報27.80%収益成長率74.37%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率87.95%株主資本利益率n/aネット・マージン-817.19%前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • May 19CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/18/2026, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jan 14Cannapharmarx, Inc. Announces Resignation of Director Rick Orman, Effective January 8, 2026CannaPharmaRX, Inc. announced that on January 8, 2026, Rick Orman informed the Board of Directors of his resignation as a member of the Board effective immediately. Mr. Orman's resignation from the Board did not indicate it was the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies, or practices of the Company.お知らせ • Aug 22Cannapharmarx, Inc. Announces Revenue Guidance for Third Quarter 2025CannaPharmaRX, Inc. announced revenue guidance for third quarter 2025. The company projects revenues of approximately CAD 1,050,000, with the anticipation of additional shipments before the end of September. This forecast may vary slightly depending on fluctuations in the Euro-to-Canadian Dollar exchange rate.お知らせ • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/16/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 04/01/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jun 06CannaPharmaRX, Inc. Announces CEO ChangesCannaPharmaRx, Inc. announced that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO duties earlier this month and will guide the company through its rapid growth phase. Mr. Medwid is a dynamic senior operations executive with more than thirty years of experience in both public and private markets with a focus on scalable process engineering, brand development and strategic partnerships. He has been recognized with numerous business awards and accolades, including Profit 100's Top 100 in Canada, five years in a row while a partner in Seattle's Best Coffee, additionally was a awarded the recognition of being one of Vancouver's Top 40 Under 40. Mr. Medwid recently exited his prior company in the retail cannabis sector and looks forward to bringing that background to the company as they target new revenue opportunities this year. His strengths include driving growth through the expansion of market segments and geography resulting in multi-year growth. Mr. Medwid also has extensive experience creating internal processes for departmental budgets, technology standards and human resource policies resulting in an engaged workforce as well as developing corporate governance aligned to generally accepted accounting principles. Mr. Medwid has a demonstrated history of increasing corporate performance through the management of process design, customer relationships, strategic planning along with a focused initiative of data-driven change management and utilized these skills as President of other successful publicly traded companies with operations in multiple countries.お知らせ • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/15/2024, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Mar 28CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 03/27/2024, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 11/14/2023, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 15CannaPharmaRX, Inc. Announces Executive ChangesEffective October 13, 2023, John Cassels is being replaced as the Chief Financial Officer (“CFO”) of CannPharmaRX, Inc. effective June 1, 2023. There was no disagreement between and Mr. Cassels on any matter related to operations, policies or practices that led to Mr. Cassels’s replacement as CFO. Effective October 13, 2023, Board of Directors has determined to appoint Oliver Foeste as Chief Financial Officer. Mr. Foeste has consented to such appointment. Mr. Foeste is the founder and Managing Partner of Invictus Accounting Group LLP and has significant executive, director, finance, and public company compliance experience across a number of industry sectors including cannabis and nutraceuticals. Prior to Invictus, Mr. Foeste was in senior finance and accounting roles at TSX, TSXV, and NYSE listed issuers, and earned his CPA at Deloitte and a boutique tax advisory firm.お知らせ • Aug 26CannaPharmaRx Expands Board of DirectorsCannaPharmaRX, Inc. announced that it has expanded its board of directors from three seats to five. The board deemed this expansion was in the best interest of the corporation as it coincides with an expansion of operations. The following person(s) were elected to the Board to fill the newly created directorships until the next annual meeting of stockholders of the corporation: Mr. Anthony Panek, age 38, is a corporate mergers and acquisitions attorney and venture capital investor with expertise in capital raising formation and growing businesses. He has worked with private equity and venture capital funds to allocate capital to emerging growth companies and works with emerging growth companies, both public and private, to raise capital and acquire assets and corporate talent. He has been an investor in many emerging growth companies and private funds investing in similar companies. He works with companies from a business and legal perspective to navigate and manage growth challenges facing emerging growth companies and helping companies complying with their SEC reporting obligations. He completed the Venture Capital Certificate Program at Startup@Berkeley Law. Mr. Panek was selected to serve on the Company's Board based upon his experience as an attorney and venture capital and private equity investor helping emerging companies raise capital, comply with SEC reporting and governance requirements, and his work with other cannabis companies. Mr. Adam Mindle, age 52, is a transactional attorney with extensive experience in structuring, negotiating and documenting sophisticated joint ventures, secured financing and mergers and acquisitions related to real estate, healthcare and technology companies. In 2010, Mr. Mindle co-founded Greystone Law Group LLP. Prior to co-founding Greystone Law Group LLP, Mr. Mindle was a partner in the Los Angeles officer of Orrick, Herrington & Sutcliffe LLP. Mr. Mindle is a veteran authority on real estate, finance and corporate transactions having represented real estate developers, private equity funds, pension funds, REITs, public and private companies and institutional lenders in connection with the acquisition and disposition of real estate assets, secured financing and joint ventures. During his three-decade career, Mr. Mindle has guided numerous start-up companies, mature organizations, pension funds, REITs and other public and private companies through a myriad of sophisticated transactions valued in billions of dollars. The third and final board position will look to be filled in the near future. Mark Branson has chosen to step down from his current position on the Board.お知らせ • Jun 24CannaPharmaRX, Inc. Announces CEO ChangesCannaPharmaRx, Inc. announced that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO duties earlier this month and will guide the company through its rapid growth phase. Mr. Medwid is a dynamic senior operations executive with more than thirty years of experience in both public and private markets with a focus on scalable process engineering, brand development and strategic partnerships. He has been recognized with numerous business awards and accolades, including Profit 100's Top 100 in Canada, five years in a row while a partner in Seattle's Best Coffee, additionally was a awarded the recognition of being one of Vancouver's Top 40 Under 40. Mr. Medwid recently exited his prior company in the retail cannabis sector and looks forward to bringing that background to the company as they target new revenue opportunities this year. His strengths include driving growth through the expansion of market segments and geography resulting in multi-year growth. Mr. Medwid also has extensive experience creating internal processes for departmental budgets, technology standards and human resource policies resulting in an engaged workforce as well as developing corporate governance aligned to generally accepted accounting principles. Mr. Medwid has a demonstrated history of increasing corporate performance through the management of process design, customer relationships, strategic planning along with a focused initiative of data-driven change management and utilized these skills as President of other successful publicly traded companies with operations in multiple countries.お知らせ • Jan 12CannaPharmaRx Receives Canada Revenue Agency (CRA) License As Final Step to Bringing Facility Into Production With Annual Revenues of Over $30 Million ExpectedCannaPharmaRx, Inc. announced that it has received its CRA license. A company can start producing cannabis products after receiving licensing from both the CRA and Health Canada. CannaPharmaRx can now begin business activities relating to the production and sale of cannabis. The license is valid for up to two years. CannaPharmaRx is now authorized to grow cannabis and sell wholesale to other licensed producers throughout Canada. The CRA oversees regulation of cannabis products including the production, possession, removal, sale and distribution of cannabis as well as impose proper excise duties and taxes on cannabis products. Now that both licenses are approved the company anticipates completing the first harvest during the current quarter with estimated annual revenue over $30 million.お知らせ • Dec 22+ 2 more updatesCannaPharmaRx, Inc Receives Cultivation License from Health Canada and Projects 2023 Revenue over $30 MillionCannaPharmaRx, Inc. announced Health Canada has issued a cultivation license to the Company. As a result, CannaPharmaRx may now legally grow cannabis and sell its crop to other licensed producers and licensed wholesalers throughout Canada. Health Canada is the department of the federal government of Canada responsible for national health policy. It approves and oversees the production of all cannabis products and is the licensing authority for all companies involved in the cannabis industry. Health Canada requires that all cannabis products meet federal regulatory requirements before they can be sold in Canada. The new license, denominated LIC-3JCQW6DIU0, is among the final major steps prior to production. This type of standard cultivation license is a prerequisite for licensed cannabis cultivators wanting to build and grow in a large-scale facility in order to expand their enterprise. Approval of the cultivation license allows the company to reasonably project completion of its initial first harvest and commence sales from the crop during First Quarter 2023 resulting in estimated 12 month revenues of $30 million.お知らせ • Nov 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 11/14/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 13CannaPharmaRX, Inc. announced delayed 10-Q filingOn 08/12/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/16/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 03/31/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 11CannaPharmaRX, Inc. (OTCPK:CPMD) signed a letter of intent to acquire Operating Cannabis Facility Located in Braman, Oklahoma.CannaPharmaRX, Inc. (OTCPK:CPMD) signed a letter of intent to acquire Operating Cannabis Facility Located in Braman, Oklahoma on February 10, 2022. The purchase will be completed via a secured note and will include the transfer of licenses. The transaction is expected to close prior to March 31, 2022.お知らせ • Jun 09An unknown buyer entered in an agreement to acquire Hanover, Ontario Facility for CAD 2 million.An unknown buyer entered in an agreement to acquire Hanover, Ontario Facility for CAD 2 million on June 8, 2021. The proceeds of the sale will provide working capital, allowing the facility to become production ready in a short period of time. Senior management unanimously agreed a sale was most beneficial for the company and its stakeholders. The deal is expected to close on June 30, 2021.お知らせ • Apr 03CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 04/01/2021, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 29CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a definitive agreement to acquire Assets and Facilities Located in Saskatoon, Saskatchewan for CAD 12 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a definitive agreement to acquire Assets and Facilities Located in Saskatoon, Saskatchewan for CAD 12 million on January 18, 2021. The purchase price is subject to adjustments. CannaPharmaRX will pay the purchase price for the facility which means the sum of: (i) CAD 12 million and (ii) the CannaPharmaRX share of the option purchase price, not including goods and services tax. The payment schedule for the purchase price will be a deposit of CAD 0.1 million will be paid on execution of the agreement, CAD 5.9 million, plus 50% of the share of the option purchase price, plus the deposit, together with any goods and services tax thereon, subject to adjustments as hereinafter described, shall be paid to the seller’s solicitor on or before the closing date; then CAD 3 million plus the remaining 50% of the share of the option purchase price, together with any goods and services tax thereon, shall be paid within 3 Business Days of the Cultivation Licensing Approval Date; and then CAD 3 million together with any goods and services tax thereon, shall be paid within 3 Business Days of the Processing Licensing Approval Date. The transaction is subject to satisfaction of due diligence, board approval and certain closing conditions. The transaction is expected to close in February 2021.お知らせ • Jan 13CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a Purchase and Sale Agreement to acquire assets and facilities in Cremona AB for CAD 12 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a Purchase and Sale Agreement to acquire assets and facilities in Cremona AB for CAD 12 million on January 7, 2021. The company will pay the “Purchase Price” for the facility which means the sum of: (i) CAD 12 million and (ii) the Purchaser’s Share of the Option Purchase Price, not including Goods and Services Tax. The payment schedule for the Purchase Price will be a deposit of CAD 0.1 million paid on execution of the PSA, the CAD 5.9 million, plus 50% of the Purchaser’s Share of the Option Purchase Price, plus the deposit, together with any Goods and Services Tax thereon, subject to adjustments as hereinafter described, shall be paid to the Seller’s solicitor on or before the closing date; then CAD 3 million plus the remaining 50% of the Purchaser’s Share of the Option Purchase Price, together with any Goods and Services Tax thereon, shall be paid within 3 Business Days of the Cultivation Licensing Approval Date; and then CAD 3 million, together with any Goods and Services Tax thereon, shall be paid within 3 Business Days of the Processing Licensing Approval Date. The transaction is subject to certain closing conditions and is scheduled to close in February 2021.お知らせ • Aug 19CannaPharmaRX, Inc. announced that it has received $3 million in funding from Triton Funds LLCCannaPharmaRX, Inc. (OTCPK:CPMD) announced that it has received $3,000,000 in a round of funding from new investor Triton Funds LLC on August 18, 2020.お知らせ • Aug 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 08/14/2020, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 07CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a purchase agreement to acquire Cannabis Production Facility in Cathedral City, California from Bristol Capital Advisors, LLC for $10 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a purchase agreement to acquire Cannabis Production Facility in Cathedral City, California from Bristol Capital Advisors, LLC for $10 million on June 24, 2020. The acquisition is anticipated to close during the next 45 days, subject to CannapharmaRx receiving appropriate funding. Bennett J. Yankowitz of Shumaker Mallory LLP acted as legal advisor to Bristol, Joshua D. Brinen of Brinen & Associates, LLC acted as legal advisor to CannaPharmaRX.収支内訳CannaPharmaRX の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:CPMD 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Dec 251-111030 Sep 252-71030 Jun 251-60031 Mar 25110031 Dec 241-101030 Sep 24010030 Jun 24010031 Mar 240-71031 Dec 23041030 Sep 230-75030 Jun 230-85031 Mar 230-85031 Dec 220-95030 Sep 220-122030 Jun 220-122031 Mar 220-123031 Dec 210-93030 Sep 210-134030 Jun 210-155031 Mar 210-145031 Dec 200-205030 Sep 200-184030 Jun 200-243031 Mar 200-243031 Dec 190-203030 Sep 190-132030 Jun 190-52031 Mar 190-41031 Dec 180-31030 Sep 180-10030 Jun 18000031 Mar 18000031 Dec 17000030 Sep 17000030 Jun 17000031 Mar 17000031 Dec 160-11030 Sep 160-55030 Jun 160-77031 Mar 160-1111031 Dec 150-1212030 Sep 150-1190質の高い収益: CPMDは現在利益が出ていません。利益率の向上: CPMDは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: CPMDは利益を出していないが、過去 5 年間で年間27.8%の割合で損失を削減してきた。成長の加速: CPMDの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: CPMDは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -5% ) と比較することは困難です。株主資本利益率高いROE: CPMDの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 12:24終値2026/05/20 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CannaPharmaRX, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 19CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/18/2026, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jan 14Cannapharmarx, Inc. Announces Resignation of Director Rick Orman, Effective January 8, 2026CannaPharmaRX, Inc. announced that on January 8, 2026, Rick Orman informed the Board of Directors of his resignation as a member of the Board effective immediately. Mr. Orman's resignation from the Board did not indicate it was the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies, or practices of the Company.
お知らせ • Aug 22Cannapharmarx, Inc. Announces Revenue Guidance for Third Quarter 2025CannaPharmaRX, Inc. announced revenue guidance for third quarter 2025. The company projects revenues of approximately CAD 1,050,000, with the anticipation of additional shipments before the end of September. This forecast may vary slightly depending on fluctuations in the Euro-to-Canadian Dollar exchange rate.
お知らせ • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/16/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 04/01/2025, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jun 06CannaPharmaRX, Inc. Announces CEO ChangesCannaPharmaRx, Inc. announced that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO duties earlier this month and will guide the company through its rapid growth phase. Mr. Medwid is a dynamic senior operations executive with more than thirty years of experience in both public and private markets with a focus on scalable process engineering, brand development and strategic partnerships. He has been recognized with numerous business awards and accolades, including Profit 100's Top 100 in Canada, five years in a row while a partner in Seattle's Best Coffee, additionally was a awarded the recognition of being one of Vancouver's Top 40 Under 40. Mr. Medwid recently exited his prior company in the retail cannabis sector and looks forward to bringing that background to the company as they target new revenue opportunities this year. His strengths include driving growth through the expansion of market segments and geography resulting in multi-year growth. Mr. Medwid also has extensive experience creating internal processes for departmental budgets, technology standards and human resource policies resulting in an engaged workforce as well as developing corporate governance aligned to generally accepted accounting principles. Mr. Medwid has a demonstrated history of increasing corporate performance through the management of process design, customer relationships, strategic planning along with a focused initiative of data-driven change management and utilized these skills as President of other successful publicly traded companies with operations in multiple countries.
お知らせ • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/15/2024, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Mar 28CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 03/27/2024, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 11/14/2023, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 15CannaPharmaRX, Inc. Announces Executive ChangesEffective October 13, 2023, John Cassels is being replaced as the Chief Financial Officer (“CFO”) of CannPharmaRX, Inc. effective June 1, 2023. There was no disagreement between and Mr. Cassels on any matter related to operations, policies or practices that led to Mr. Cassels’s replacement as CFO. Effective October 13, 2023, Board of Directors has determined to appoint Oliver Foeste as Chief Financial Officer. Mr. Foeste has consented to such appointment. Mr. Foeste is the founder and Managing Partner of Invictus Accounting Group LLP and has significant executive, director, finance, and public company compliance experience across a number of industry sectors including cannabis and nutraceuticals. Prior to Invictus, Mr. Foeste was in senior finance and accounting roles at TSX, TSXV, and NYSE listed issuers, and earned his CPA at Deloitte and a boutique tax advisory firm.
お知らせ • Aug 26CannaPharmaRx Expands Board of DirectorsCannaPharmaRX, Inc. announced that it has expanded its board of directors from three seats to five. The board deemed this expansion was in the best interest of the corporation as it coincides with an expansion of operations. The following person(s) were elected to the Board to fill the newly created directorships until the next annual meeting of stockholders of the corporation: Mr. Anthony Panek, age 38, is a corporate mergers and acquisitions attorney and venture capital investor with expertise in capital raising formation and growing businesses. He has worked with private equity and venture capital funds to allocate capital to emerging growth companies and works with emerging growth companies, both public and private, to raise capital and acquire assets and corporate talent. He has been an investor in many emerging growth companies and private funds investing in similar companies. He works with companies from a business and legal perspective to navigate and manage growth challenges facing emerging growth companies and helping companies complying with their SEC reporting obligations. He completed the Venture Capital Certificate Program at Startup@Berkeley Law. Mr. Panek was selected to serve on the Company's Board based upon his experience as an attorney and venture capital and private equity investor helping emerging companies raise capital, comply with SEC reporting and governance requirements, and his work with other cannabis companies. Mr. Adam Mindle, age 52, is a transactional attorney with extensive experience in structuring, negotiating and documenting sophisticated joint ventures, secured financing and mergers and acquisitions related to real estate, healthcare and technology companies. In 2010, Mr. Mindle co-founded Greystone Law Group LLP. Prior to co-founding Greystone Law Group LLP, Mr. Mindle was a partner in the Los Angeles officer of Orrick, Herrington & Sutcliffe LLP. Mr. Mindle is a veteran authority on real estate, finance and corporate transactions having represented real estate developers, private equity funds, pension funds, REITs, public and private companies and institutional lenders in connection with the acquisition and disposition of real estate assets, secured financing and joint ventures. During his three-decade career, Mr. Mindle has guided numerous start-up companies, mature organizations, pension funds, REITs and other public and private companies through a myriad of sophisticated transactions valued in billions of dollars. The third and final board position will look to be filled in the near future. Mark Branson has chosen to step down from his current position on the Board.
お知らせ • Jun 24CannaPharmaRX, Inc. Announces CEO ChangesCannaPharmaRx, Inc. announced that the company has appointed a new CEO. Dean Medwid succeeds Domenic Colvin, who will stay with the company providing leadership and vision. Mr. Medwid assumed CEO duties earlier this month and will guide the company through its rapid growth phase. Mr. Medwid is a dynamic senior operations executive with more than thirty years of experience in both public and private markets with a focus on scalable process engineering, brand development and strategic partnerships. He has been recognized with numerous business awards and accolades, including Profit 100's Top 100 in Canada, five years in a row while a partner in Seattle's Best Coffee, additionally was a awarded the recognition of being one of Vancouver's Top 40 Under 40. Mr. Medwid recently exited his prior company in the retail cannabis sector and looks forward to bringing that background to the company as they target new revenue opportunities this year. His strengths include driving growth through the expansion of market segments and geography resulting in multi-year growth. Mr. Medwid also has extensive experience creating internal processes for departmental budgets, technology standards and human resource policies resulting in an engaged workforce as well as developing corporate governance aligned to generally accepted accounting principles. Mr. Medwid has a demonstrated history of increasing corporate performance through the management of process design, customer relationships, strategic planning along with a focused initiative of data-driven change management and utilized these skills as President of other successful publicly traded companies with operations in multiple countries.
お知らせ • Jan 12CannaPharmaRx Receives Canada Revenue Agency (CRA) License As Final Step to Bringing Facility Into Production With Annual Revenues of Over $30 Million ExpectedCannaPharmaRx, Inc. announced that it has received its CRA license. A company can start producing cannabis products after receiving licensing from both the CRA and Health Canada. CannaPharmaRx can now begin business activities relating to the production and sale of cannabis. The license is valid for up to two years. CannaPharmaRx is now authorized to grow cannabis and sell wholesale to other licensed producers throughout Canada. The CRA oversees regulation of cannabis products including the production, possession, removal, sale and distribution of cannabis as well as impose proper excise duties and taxes on cannabis products. Now that both licenses are approved the company anticipates completing the first harvest during the current quarter with estimated annual revenue over $30 million.
お知らせ • Dec 22+ 2 more updatesCannaPharmaRx, Inc Receives Cultivation License from Health Canada and Projects 2023 Revenue over $30 MillionCannaPharmaRx, Inc. announced Health Canada has issued a cultivation license to the Company. As a result, CannaPharmaRx may now legally grow cannabis and sell its crop to other licensed producers and licensed wholesalers throughout Canada. Health Canada is the department of the federal government of Canada responsible for national health policy. It approves and oversees the production of all cannabis products and is the licensing authority for all companies involved in the cannabis industry. Health Canada requires that all cannabis products meet federal regulatory requirements before they can be sold in Canada. The new license, denominated LIC-3JCQW6DIU0, is among the final major steps prior to production. This type of standard cultivation license is a prerequisite for licensed cannabis cultivators wanting to build and grow in a large-scale facility in order to expand their enterprise. Approval of the cultivation license allows the company to reasonably project completion of its initial first harvest and commence sales from the crop during First Quarter 2023 resulting in estimated 12 month revenues of $30 million.
お知らせ • Nov 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 11/14/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 13CannaPharmaRX, Inc. announced delayed 10-Q filingOn 08/12/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17CannaPharmaRX, Inc. announced delayed 10-Q filingOn 05/16/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 03/31/2022, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 11CannaPharmaRX, Inc. (OTCPK:CPMD) signed a letter of intent to acquire Operating Cannabis Facility Located in Braman, Oklahoma.CannaPharmaRX, Inc. (OTCPK:CPMD) signed a letter of intent to acquire Operating Cannabis Facility Located in Braman, Oklahoma on February 10, 2022. The purchase will be completed via a secured note and will include the transfer of licenses. The transaction is expected to close prior to March 31, 2022.
お知らせ • Jun 09An unknown buyer entered in an agreement to acquire Hanover, Ontario Facility for CAD 2 million.An unknown buyer entered in an agreement to acquire Hanover, Ontario Facility for CAD 2 million on June 8, 2021. The proceeds of the sale will provide working capital, allowing the facility to become production ready in a short period of time. Senior management unanimously agreed a sale was most beneficial for the company and its stakeholders. The deal is expected to close on June 30, 2021.
お知らせ • Apr 03CannaPharmaRX, Inc. announced delayed annual 10-K filingOn 04/01/2021, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 29CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a definitive agreement to acquire Assets and Facilities Located in Saskatoon, Saskatchewan for CAD 12 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a definitive agreement to acquire Assets and Facilities Located in Saskatoon, Saskatchewan for CAD 12 million on January 18, 2021. The purchase price is subject to adjustments. CannaPharmaRX will pay the purchase price for the facility which means the sum of: (i) CAD 12 million and (ii) the CannaPharmaRX share of the option purchase price, not including goods and services tax. The payment schedule for the purchase price will be a deposit of CAD 0.1 million will be paid on execution of the agreement, CAD 5.9 million, plus 50% of the share of the option purchase price, plus the deposit, together with any goods and services tax thereon, subject to adjustments as hereinafter described, shall be paid to the seller’s solicitor on or before the closing date; then CAD 3 million plus the remaining 50% of the share of the option purchase price, together with any goods and services tax thereon, shall be paid within 3 Business Days of the Cultivation Licensing Approval Date; and then CAD 3 million together with any goods and services tax thereon, shall be paid within 3 Business Days of the Processing Licensing Approval Date. The transaction is subject to satisfaction of due diligence, board approval and certain closing conditions. The transaction is expected to close in February 2021.
お知らせ • Jan 13CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a Purchase and Sale Agreement to acquire assets and facilities in Cremona AB for CAD 12 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a Purchase and Sale Agreement to acquire assets and facilities in Cremona AB for CAD 12 million on January 7, 2021. The company will pay the “Purchase Price” for the facility which means the sum of: (i) CAD 12 million and (ii) the Purchaser’s Share of the Option Purchase Price, not including Goods and Services Tax. The payment schedule for the Purchase Price will be a deposit of CAD 0.1 million paid on execution of the PSA, the CAD 5.9 million, plus 50% of the Purchaser’s Share of the Option Purchase Price, plus the deposit, together with any Goods and Services Tax thereon, subject to adjustments as hereinafter described, shall be paid to the Seller’s solicitor on or before the closing date; then CAD 3 million plus the remaining 50% of the Purchaser’s Share of the Option Purchase Price, together with any Goods and Services Tax thereon, shall be paid within 3 Business Days of the Cultivation Licensing Approval Date; and then CAD 3 million, together with any Goods and Services Tax thereon, shall be paid within 3 Business Days of the Processing Licensing Approval Date. The transaction is subject to certain closing conditions and is scheduled to close in February 2021.
お知らせ • Aug 19CannaPharmaRX, Inc. announced that it has received $3 million in funding from Triton Funds LLCCannaPharmaRX, Inc. (OTCPK:CPMD) announced that it has received $3,000,000 in a round of funding from new investor Triton Funds LLC on August 18, 2020.
お知らせ • Aug 15CannaPharmaRX, Inc. announced delayed 10-Q filingOn 08/14/2020, CannaPharmaRX, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 07CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a purchase agreement to acquire Cannabis Production Facility in Cathedral City, California from Bristol Capital Advisors, LLC for $10 million.CannaPharmaRX, Inc. (OTCPK:CPMD) entered into a purchase agreement to acquire Cannabis Production Facility in Cathedral City, California from Bristol Capital Advisors, LLC for $10 million on June 24, 2020. The acquisition is anticipated to close during the next 45 days, subject to CannapharmaRx receiving appropriate funding. Bennett J. Yankowitz of Shumaker Mallory LLP acted as legal advisor to Bristol, Joshua D. Brinen of Brinen & Associates, LLC acted as legal advisor to CannaPharmaRX.